HomeE2XA34 • BVMF
add
Exact Sciences Corp
Previous close
R$32.45
Day range
R$32.45 - R$32.45
Year range
R$22.74 - R$42.10
Market cap
9.91B USD
Avg Volume
544.00
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 708.66M | 12.78% |
Operating expense | 531.08M | -0.43% |
Net income | -38.24M | -4,915.62% |
Net profit margin | -5.40 | -4,253.85% |
Earnings per share | -0.13 | 59.97% |
EBITDA | 36.28M | 270.41% |
Effective tax rate | -2.16% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.02B | 39.04% |
Total assets | 6.75B | 5.10% |
Total liabilities | 3.54B | 7.23% |
Total equity | 3.21B | — |
Shares outstanding | 185.08M | — |
Price to book | 1.87 | — |
Return on assets | -0.69% | — |
Return on capital | -0.77% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -38.24M | -4,915.62% |
Cash from operations | 138.72M | 469.43% |
Cash from investing | -81.72M | -147.86% |
Cash from financing | -226.00K | -345.65% |
Net change in cash | 58.65M | 701.48% |
Free cash flow | 107.80M | 982.44% |
About
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer. Wikipedia
CEO
Founded
Jan 1, 1995
Headquarters
Website
Employees
6,550
